Outcomes of universal access to antiretroviral therapy (ART) in Georgia

Tengiz Tsertsvadze, Nikoloz Chkhartishvili, Lali Sharvadze, Natia Dvali, Otar Chokoshvili, Pati Gabunia, Akaki Abutidze, Kenrad Edwin Nelson, Jack Dehovitz, Carlos Del Rio

Research output: Contribution to journalArticle

Abstract

Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76% were men, 60% were injection drug users (IDU), 59% had a history of an AIDS-defining illness, and 53% were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm3. During followup, 152 (20%) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm3 and 86% of patients had viral load

Original languageEnglish (US)
Article number621078
JournalAIDS Research and Treatment
Volume2011
DOIs
StatePublished - 2011

Fingerprint

Therapeutics
CD4 Lymphocyte Count
Hepatitis C
Drug Users
Viral Load
Acquired Immunodeficiency Syndrome
Cohort Studies
Retrospective Studies
Injections
Mortality

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology and Allergy
  • Infectious Diseases
  • Dermatology

Cite this

Tsertsvadze, T., Chkhartishvili, N., Sharvadze, L., Dvali, N., Chokoshvili, O., Gabunia, P., ... Del Rio, C. (2011). Outcomes of universal access to antiretroviral therapy (ART) in Georgia. AIDS Research and Treatment, 2011, [621078]. https://doi.org/10.1155/2011/621078

Outcomes of universal access to antiretroviral therapy (ART) in Georgia. / Tsertsvadze, Tengiz; Chkhartishvili, Nikoloz; Sharvadze, Lali; Dvali, Natia; Chokoshvili, Otar; Gabunia, Pati; Abutidze, Akaki; Nelson, Kenrad Edwin; Dehovitz, Jack; Del Rio, Carlos.

In: AIDS Research and Treatment, Vol. 2011, 621078, 2011.

Research output: Contribution to journalArticle

Tsertsvadze, T, Chkhartishvili, N, Sharvadze, L, Dvali, N, Chokoshvili, O, Gabunia, P, Abutidze, A, Nelson, KE, Dehovitz, J & Del Rio, C 2011, 'Outcomes of universal access to antiretroviral therapy (ART) in Georgia', AIDS Research and Treatment, vol. 2011, 621078. https://doi.org/10.1155/2011/621078
Tsertsvadze T, Chkhartishvili N, Sharvadze L, Dvali N, Chokoshvili O, Gabunia P et al. Outcomes of universal access to antiretroviral therapy (ART) in Georgia. AIDS Research and Treatment. 2011;2011. 621078. https://doi.org/10.1155/2011/621078
Tsertsvadze, Tengiz ; Chkhartishvili, Nikoloz ; Sharvadze, Lali ; Dvali, Natia ; Chokoshvili, Otar ; Gabunia, Pati ; Abutidze, Akaki ; Nelson, Kenrad Edwin ; Dehovitz, Jack ; Del Rio, Carlos. / Outcomes of universal access to antiretroviral therapy (ART) in Georgia. In: AIDS Research and Treatment. 2011 ; Vol. 2011.
@article{5c0e0c3f859f4aeeab505453d94a8c0b,
title = "Outcomes of universal access to antiretroviral therapy (ART) in Georgia",
abstract = "Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76{\%} were men, 60{\%} were injection drug users (IDU), 59{\%} had a history of an AIDS-defining illness, and 53{\%} were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm3. During followup, 152 (20{\%}) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm3 and 86{\%} of patients had viral load",
author = "Tengiz Tsertsvadze and Nikoloz Chkhartishvili and Lali Sharvadze and Natia Dvali and Otar Chokoshvili and Pati Gabunia and Akaki Abutidze and Nelson, {Kenrad Edwin} and Jack Dehovitz and {Del Rio}, Carlos",
year = "2011",
doi = "10.1155/2011/621078",
language = "English (US)",
volume = "2011",
journal = "AIDS Research and Treatment",
issn = "2090-1240",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Outcomes of universal access to antiretroviral therapy (ART) in Georgia

AU - Tsertsvadze, Tengiz

AU - Chkhartishvili, Nikoloz

AU - Sharvadze, Lali

AU - Dvali, Natia

AU - Chokoshvili, Otar

AU - Gabunia, Pati

AU - Abutidze, Akaki

AU - Nelson, Kenrad Edwin

AU - Dehovitz, Jack

AU - Del Rio, Carlos

PY - 2011

Y1 - 2011

N2 - Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76% were men, 60% were injection drug users (IDU), 59% had a history of an AIDS-defining illness, and 53% were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm3. During followup, 152 (20%) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm3 and 86% of patients had viral load

AB - Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76% were men, 60% were injection drug users (IDU), 59% had a history of an AIDS-defining illness, and 53% were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm3. During followup, 152 (20%) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm3 and 86% of patients had viral load

UR - http://www.scopus.com/inward/record.url?scp=84861013972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861013972&partnerID=8YFLogxK

U2 - 10.1155/2011/621078

DO - 10.1155/2011/621078

M3 - Article

VL - 2011

JO - AIDS Research and Treatment

JF - AIDS Research and Treatment

SN - 2090-1240

M1 - 621078

ER -